Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Massachusetts General Hospital
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Lecia V. Sequist, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01746251
First received: November 27, 2012
Last updated: November 26, 2013
Last verified: November 2013

November 27, 2012
November 26, 2013
January 2013
January 2015   (final data collection date for primary outcome measure)
Recurrence-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
The primary objective of this study is to demonstrate that prolonged adjuvant therapy with afatinib will improve recurrence free survival (RFS) compared to a concise adjuvant course in patients with resected stage I-III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation.
Same as current
Complete list of historical versions of study NCT01746251 on ClinicalTrials.gov Archive Site
  • Number of patients with adverse events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    To determine the safety and tolerability of adjuvant afatinib
  • Molecular genotype of recurrent cancers [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    We aim to collect clinical data from patients with recurrent NSCLC after treatment with adjuvant afatinib, including molecular characteristics of recurrent cancer analyzed as part of routine care, and time to treatment failure for patients treated with alternative chemotherapies for recurrent lung cancer.
  • overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate overall survival
Same as current
Not Provided
Not Provided
 
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied. It also means that the FDA has not yet approved afatinib for use in patients.

In this research study the investigators are looking to see if taking afatinib after surgery works better when taken over a short period of time, compared to a long period of time.

In order to determine if one is eligible to participate in this study they would be asked to undergo some screening tests or procedures. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that one does not take part in the research study. If the patient has had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include: a medical history, performance status, physical exam and vital signs including height and weight, an assessment of your tumor, routine blood tests, pregnancy test, electrocardiogram, echocardiogram and/or multigated acquisition scan. If these tests show that a patient is eligible to participate in the research study, they will begin the study treatment. If one does not meet the eligibility criteria, they will not be able to participate in this research study.

Because no one knows which of the study options is best, the patients will be "randomized" into one of the study groups. They will take afatinib by mouth every day for either 3 months (short course) or for 2 years (long course). Randomization means that one is put into a group by chance. It is like flipping a coin. Neither the patient, nor the research doctor will choose what group the patient will be in. You will have a 50/50 chance of being placed in any group.

Regardless of which study group one is put in, all patients will take afatinib by mouth every day. The first cycle will last 28 days. All cycles after that will last 25-31 days. Patients will take their medication (tablets) by mouth once a day, at about the same time each day. They should take afatinib with a glass of water. Afatinb treatment will continue until the assigned course is completed, or until there are side effects that cannot be tolerated, or one decides to stop study treatment, of if the lung cancer returns.

Patients will be asked to come to the clinic at the following time points:

  • Day 1 and 8 of Cycle 1
  • Day 1 of Cycles 2, 3 and 4
  • Off treatment visit-28 days after the last dose of study drug

If one is assigned to the long course, one will also need to come in for clinic visits on Day 1 of Cycles 7, 10, 13, 16, 19, 22 and 25. If one is assigned to the short course, one does not need to come in for these additional clinic visits.

The following tests and procedures will be done to monitor for side effects of afatinib.

  • Routine blood tests-about 2 tablespoons of blood
  • Performance status
  • Physical exam and vital signs, including height and weight

The following tests and procedures will be done to monitor for recurrence of lung cancer. These visits are the same, regardless of whether one is taking a short course, or a long course of afatinib. There will be clinic visits once every 6 months for 3 years (months 7, 13, 19, 25, 31, 37 and 49), and then one more visit 1 year later. The following tests and procedures will be done at these follow up visits: a CT scan of the chest, routine blood tests, performance status and a physical exam, including height and weight.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Non Small Cell Lung Cancer
Drug: Afatinib
  • Active Comparator: Concise Afatinib
    Afatinib oral daily dose for 3 months
    Intervention: Drug: Afatinib
  • Active Comparator: Prolonged Afatinib
    Afatinib oral daily dose for 2 years
    Intervention: Drug: Afatinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
92
Not Provided
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pathologically confirmed diagnosis of non-small cell lung cancer with EGFR mutation
  • Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by AJCC 7th Edition staging criteria
  • Surgical resection with curative intent was at least 6 months prior to enrollment
  • At least 3 weeks have passed since completion of adjuvant chemotherapy or radiotherapy

Exclusion Criteria:

  • Pregnant or breastfeeding
  • History of allergic reactions attributed to compounds of similar chemical composition to afatinib
  • Prior exposure to EGFR tyrosine kinase inhibitor
  • Evidence of clinically active interstitial lung disease
  • Radiographic evidence of recurrent NSCLC prior to afatinib treatment
  • Receipt of any experimental treatment within 30 days of start of treatment with afatinib until the end of treatment visit
  • Use of potent P-gp inhibitors and potent P-gp inducers must be avoided during treatment with afatinib
  • Individuals with a history of a different malignancy (except: synchronous or metachronous primary non-small cell lung cancers of lower stage than the cancer for which adjuvant treatment is currently being prescribed; disease free for at least 3 years; cervical cancer in situ; basal or squamous cell carcinoma of the skin)
  • HIV positive on combination antiretroviral therapy
  • Uncontrolled intercurrent illness
Both
18 Years and older
No
Contact: Lecia Sequist, MD, MPH 617-724-4000 lvsequist@partners.org
United States
 
NCT01746251
12-504
Yes
Lecia V. Sequist, Massachusetts General Hospital
Massachusetts General Hospital
National Comprehensive Cancer Network
Principal Investigator: Lecia Sequist, MD, MPH Massachusetts General Hospital
Massachusetts General Hospital
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP